Sfoglia per Autore
Ductal breast carcinoma metastatic to the stomach resembling primary linitis plastica in a male patient
2016 Ricciuti B.; Leonardi G.C.; Ravaioli N.; De Giglio A.; Brambilla M.; Prosperi E.; Ribacchi F.; Meacci M.; Crino L.; Maiettini D.; Chiari R.; Metro G.
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Rationale, evidence and place in therapy
2017 Ricciuti B.; Baglivo S.; Paglialunga L.; De Giglio A.; Bellezza G.; Chiari R.; Crino L.; Metro G.
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation
2018 Baglivo S.; Ricciuti B.; Ludovini V.; Metro G.; Siggillino A.; De Giglio A.; Chiari R.
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
2018 Ricciuti B.; De Giglio A.; Mecca C.; Arcuri C.; Marini S.; Metro G.; Baglivo S.; Sidoni A.; Bellezza G.; Crino L.; Chiari R.
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?
2018 De Giglio A.; Porreca R.; Brambilla M.; Metro G.; Prosperi E.; Bellezza G.; Pirro M.; Chiari R.; Ricciuti B.
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
2018 Ricciuti B.; Baglivo S.; De Giglio A.; Chiari R.
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
2019 Ricciuti B.; Genova C.; De Giglio A.; Bassanelli M.; Dal Bello M.G.; Metro G.; Brambilla M.; Baglivo S.; Grossi F.; Chiari R.
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable
2019 Cortellini A.; Bersanelli M.; Buti S.; Cannita K.; Santini D.; Perrone F.; Giusti R.; Tiseo M.; Michiara M.; Di Marino P.; Tinari N.; De Tursi M.; Zoratto F.; Veltri E.; Marconcini R.; Malorgio F.; Russano M.; Anesi C.; Zeppola T.; Filetti M.; Marchetti P.; Botticelli A.; Antonini Cappellini G.C.; De Galitiis F.; Vitale M.G.; Rastelli F.; Pergolesi F.; Berardi R.; Rinaldi S.; Tudini M.; Silva R.R.; Pireddu A.; Atzori F.; Chiari R.; Ricciuti B.; De Giglio A.; Iacono D.; Gelibter A.; Occhipinti M.A.; Parisi A.; Porzio G.; Fargnoli M.C.; Ascierto P.A.; Ficorella C.; Natoli C.
Primary angiosarcoma of the kidney: Case report and comprehensive literature review
2019 Boni A.; Cochetti G.; Sidoni A.; Bellezza G.; Lepri E.; De Giglio A.; Turco M.; Vermandois J.A.R.D.; Zingaro M.D.; Cirocchi R.; Mearini E.
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression
2019 Ricciuti B.; Genova C.; Bassanelli M.; De Giglio A.; Brambilla M.; Metro G.; Baglivo S.; Dal Bello M.G.; Ceribelli A.; Grossi F.; Chiari R.
Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis
2019 Abu-Sbeih H.; Ali F.S.; Naqash A.R.; Owen D.H.; Patel S.; Otterson G.A.; Kendra K.; Ricciuti B.; Chiari R.; De Giglio A.; Sleiman J.; Funchain P.; Wills B.; Zhang J.; Naidoo J.; Philpott J.; Gao J.; Subudhi S.K.; Wang Y.
Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies
2019 de Giglio A.; Nuvola G.; Gustavo Dall'Olio F.
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program
2019 Verzoni E.; Carteni G.; Cortesi E.; Giannarelli D.; De Giglio A.; Sabbatini R.; Buti S.; Rossetti S.; Cognetti F.; Rastelli F.; Sobrero A.; Turci D.; Sternberg C.N.; Porta C.; Cappuzzo F.; Tortora G.; Tassinari D.; Panni S.; Pazzola A.; Surico G.; Raimondi A.; De Giorgi U.; Procopio G.
Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics
2020 de Giglio A.; Nuvola G.; Baldini C.
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
2020 Cortellini A.; Bersanelli M.; Santini D.; Buti S.; Tiseo M.; Cannita K.; Perrone F.; Giusti R.; De Tursi M.; Zoratto F.; Marconcini R.; Russano M.; Zeppola T.; Anesi C.; Filetti M.; Marchetti P.; Botticelli A.; Gelibter A.; De Galitiis F.; Vitale M.G.; Rastelli F.; Tudini M.; Silva R.R.; Atzori F.; Chiari R.; Ricciuti B.; De Giglio A.; Migliorino M.R.; Mallardo D.; Vanella V.; Mosillo C.; Bracarda S.; Rinaldi S.; Berardi R.; Natoli C.; Ficorella C.; Porzio G.; Ascierto P.A.
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
2020 Nigro O.; Pinotti G.; De Galitiis F.; Di Pietro F.R.; Giusti R.; Filetti M.; Bersanelli M.; Lazzarin A.; Bordi P.; Catino A.; Pizzutilo P.; Galetta D.; Marchetti P.; Botticelli A.; Scagnoli S.; Russano M.; Santini D.; Torniai M.; Berardi R.; Ricciuti B.; De Giglio A.; Chiari R.; Russo A.; Adamo V.; Tudini M.; Silva R.R.; Bolzacchini E.; Giordano M.; Di Marino P.; De Tursi M.; Rijavec E.; Ghidini M.; Vallini I.; Stucci L.S.; Tucci M.; Pala L.; Conforti F.; Queirolo P.; Tanda E.; Spagnolo F.; Cecchi F.; Bracarda S.; Macrini S.; Santoni M.; Battelli N.; Fargnoli M.C.; Porzio G.; Tuzi A.; Suter M.B.; Ficorella C.; Cortellini A.
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience
2020 Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A.
Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (Nsclc) patients under immune-checkpoint inhibitors (ici)
2020 De Giglio A.; Mezquita L.; Auclin E.; Blanc-Durand F.; Riudavets M.; Caramella C.; Martinez G.; Benitez J.C.; Martin-Romano P.; El-Amarti L.; Hendriks L.; Ferrara R.; Naltet C.; Lavaud P.; Gazzah A.; Adam J.; Planchard D.; Chaput N.; Besse B.
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib
2020 De Giglio A.; Lamberti G.; Facchinetti F.; Genova C.; Andrini E.; Dal Bello M.G.; Tiseo M.; Metro G.; Chiari R.; Ricciuti B.
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer
2020 Ricciuti B.; Brambilla M.; Cortellini A.; De Giglio A.; Ficorella C.; Sidoni A.; Bellezza G.; Crino L.; Ludovini V.; Baglivo S.; Metro G.; Chiari R.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Ductal breast carcinoma metastatic to the stomach resembling primary linitis plastica in a male patient | Ricciuti B.; Leonardi G.C.; Ravaioli N.; De Giglio A.; Brambilla M.; Prosperi E.; Ribacchi F.; Me...acci M.; Crino L.; Maiettini D.; Chiari R.; Metro G. | 2016-01-01 | JOURNAL OF BREAST CANCER | - | 1.01 Articolo in rivista | - |
| Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Rationale, evidence and place in therapy | Ricciuti B.; Baglivo S.; Paglialunga L.; De Giglio A.; Bellezza G.; Chiari R.; Crino L.; Metro G. | 2017-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | ricciuti-et-al-2017-osimertinib-in-patients-with-advanced-epidermal-growth-factor-receptor-t790m-mutation-positive-non.pdf |
| Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation | Baglivo S.; Ricciuti B.; Ludovini V.; Metro G.; Siggillino A.; De Giglio A.; Chiari R. | 2018-01-01 | JOURNAL OF THORACIC ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib | Ricciuti B.; De Giglio A.; Mecca C.; Arcuri C.; Marini S.; Metro G.; Baglivo S.; Sidoni A.; Belle...zza G.; Crino L.; Chiari R. | 2018-01-01 | MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? | De Giglio A.; Porreca R.; Brambilla M.; Metro G.; Prosperi E.; Bellezza G.; Pirro M.; Chiari R.; ...Ricciuti B. | 2018-01-01 | THROMBOSIS RESEARCH | - | 1.01 Articolo in rivista | - |
| Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience | Ricciuti B.; Baglivo S.; De Giglio A.; Chiari R. | 2018-01-01 | THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE | - | 1.01 Articolo in rivista | ricciuti-et-al-2018-afatinib-in-the-first-line-treatment-of-patients-with-non-small-cell-lung-cancer-clinical-evidence.pdf |
| Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis | Ricciuti B.; Genova C.; De Giglio A.; Bassanelli M.; Dal Bello M.G.; Metro G.; Brambilla M.; Bagl...ivo S.; Grossi F.; Chiari R. | 2019-01-01 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable | Cortellini A.; Bersanelli M.; Buti S.; Cannita K.; Santini D.; Perrone F.; Giusti R.; Tiseo M.; M...ichiara M.; Di Marino P.; Tinari N.; De Tursi M.; Zoratto F.; Veltri E.; Marconcini R.; Malorgio F.; Russano M.; Anesi C.; Zeppola T.; Filetti M.; Marchetti P.; Botticelli A.; Antonini Cappellini G.C.; De Galitiis F.; Vitale M.G.; Rastelli F.; Pergolesi F.; Berardi R.; Rinaldi S.; Tudini M.; Silva R.R.; Pireddu A.; Atzori F.; Chiari R.; Ricciuti B.; De Giglio A.; Iacono D.; Gelibter A.; Occhipinti M.A.; Parisi A.; Porzio G.; Fargnoli M.C.; Ascierto P.A.; Ficorella C.; Natoli C. | 2019-01-01 | JOURNAL FOR IMMUNOTHERAPY OF CANCER | - | 1.01 Articolo in rivista | s40425-019-0527-y.pdf; 7782371.zip |
| Primary angiosarcoma of the kidney: Case report and comprehensive literature review | Boni A.; Cochetti G.; Sidoni A.; Bellezza G.; Lepri E.; De Giglio A.; Turco M.; Vermandois J.A.R....D.; Zingaro M.D.; Cirocchi R.; Mearini E. | 2019-01-01 | OPEN MEDICINE | - | 1.01 Articolo in rivista | 10.1515_med-2019-0048.pdf |
| Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression | Ricciuti B.; Genova C.; Bassanelli M.; De Giglio A.; Brambilla M.; Metro G.; Baglivo S.; Dal Bell...o M.G.; Ceribelli A.; Grossi F.; Chiari R. | 2019-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |
| Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis | Abu-Sbeih H.; Ali F.S.; Naqash A.R.; Owen D.H.; Patel S.; Otterson G.A.; Kendra K.; Ricciuti B.; ...Chiari R.; De Giglio A.; Sleiman J.; Funchain P.; Wills B.; Zhang J.; Naidoo J.; Philpott J.; Gao J.; Subudhi S.K.; Wang Y. | 2019-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | jco.19.00320.pdf |
| Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies | de Giglio A.; Nuvola G.; Gustavo Dall'Olio F. | 2019-01-01 | TRANSLATIONAL CANCER RESEARCH | - | 1.01 Articolo in rivista | 34515-PB4-8201-R6.pdf |
| Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program | Verzoni E.; Carteni G.; Cortesi E.; Giannarelli D.; De Giglio A.; Sabbatini R.; Buti S.; Rossetti... S.; Cognetti F.; Rastelli F.; Sobrero A.; Turci D.; Sternberg C.N.; Porta C.; Cappuzzo F.; Tortora G.; Tassinari D.; Panni S.; Pazzola A.; Surico G.; Raimondi A.; De Giorgi U.; Procopio G. | 2019-01-01 | JOURNAL FOR IMMUNOTHERAPY OF CANCER | - | 1.01 Articolo in rivista | s40425-019-0579-z.pdf; 40425_2019_579_MOESM1_ESM.tif |
| Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics | de Giglio A.; Nuvola G.; Baldini C. | 2020-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events | Cortellini A.; Bersanelli M.; Santini D.; Buti S.; Tiseo M.; Cannita K.; Perrone F.; Giusti R.; D...e Tursi M.; Zoratto F.; Marconcini R.; Russano M.; Zeppola T.; Anesi C.; Filetti M.; Marchetti P.; Botticelli A.; Gelibter A.; De Galitiis F.; Vitale M.G.; Rastelli F.; Tudini M.; Silva R.R.; Atzori F.; Chiari R.; Ricciuti B.; De Giglio A.; Migliorino M.R.; Mallardo D.; Vanella V.; Mosillo C.; Bracarda S.; Rinaldi S.; Berardi R.; Natoli C.; Ficorella C.; Porzio G.; Ascierto P.A. | 2020-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study | Nigro O.; Pinotti G.; De Galitiis F.; Di Pietro F.R.; Giusti R.; Filetti M.; Bersanelli M.; Lazza...rin A.; Bordi P.; Catino A.; Pizzutilo P.; Galetta D.; Marchetti P.; Botticelli A.; Scagnoli S.; Russano M.; Santini D.; Torniai M.; Berardi R.; Ricciuti B.; De Giglio A.; Chiari R.; Russo A.; Adamo V.; Tudini M.; Silva R.R.; Bolzacchini E.; Giordano M.; Di Marino P.; De Tursi M.; Rijavec E.; Ghidini M.; Vallini I.; Stucci L.S.; Tucci M.; Pala L.; Conforti F.; Queirolo P.; Tanda E.; Spagnolo F.; Cecchi F.; Bracarda S.; Macrini S.; Santoni M.; Battelli N.; Fargnoli M.C.; Porzio G.; Tuzi A.; Suter M.B.; Ficorella C.; Cortellini A. | 2020-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | Nigro_2020.pdf |
| Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience | Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppion...i E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A. | 2020-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | - |
| Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (Nsclc) patients under immune-checkpoint inhibitors (ici) | De Giglio A.; Mezquita L.; Auclin E.; Blanc-Durand F.; Riudavets M.; Caramella C.; Martinez G.; B...enitez J.C.; Martin-Romano P.; El-Amarti L.; Hendriks L.; Ferrara R.; Naltet C.; Lavaud P.; Gazzah A.; Adam J.; Planchard D.; Chaput N.; Besse B. | 2020-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-12-02827.pdf; cancers-12-02827-s001.pdf |
| Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib | De Giglio A.; Lamberti G.; Facchinetti F.; Genova C.; Andrini E.; Dal Bello M.G.; Tiseo M.; Metro... G.; Chiari R.; Ricciuti B. | 2020-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |
| Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer | Ricciuti B.; Brambilla M.; Cortellini A.; De Giglio A.; Ficorella C.; Sidoni A.; Bellezza G.; Cri...no L.; Ludovini V.; Baglivo S.; Metro G.; Chiari R. | 2020-01-01 | CLINICAL & TRANSLATIONAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile